Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium

Summary

This is a Phase I, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium \[sK+\] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of ≥40 and ≤70 mL/min/1.73m2.

Timeline

Start

2018-11-01

Primary completion

2020-03-31

Completion

2020-03-31

Outcome

Outcome not reported

Stopped: “Attendance at study sites carries risk of COVID-19 infection. Non-attendance at planned study site visits has unacceptable study related patient safety risk.”

Drugs

Indications